Rafael Suarez Del Villar Carrero

Dr. Rafael Suarez Del Villar Carrero

Emergency Department, Hospital Universitario HM Monteprincipe, Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Clinical Nutrition
Verified
Journal Article
Open access
LALuis Aldámiz-Echevarría
Luis Aldámiz-Echevarría
JHJavier de Las Heras
Javier de Las Heras
María L. CouceMaría L. Couce
María L. Couce
CACarlos Alcalde
Carlos Alcalde
IVIsidro Vitoria
Isidro Vitoria
Olatz VillateOlatz Villate
Olatz Villate
Non-alcoholic fatty liver disease (NAFLD) is characterized by fat accumulation affecting >5% of the liver volume that is not explained by alcohol abuse. It is known that fructose gives rise to NAFLD and it has been recently described that the ingestion of fructose in low amounts in aldolase B deficient mice is associated with the development of fatty liver. Therefore, it is reasonable that patients with HFI (Hereditary Fructose Intolerance) present fatty liver at diagnosis, but its prevalence in patients treated and with adequate follow-up is not well documented in the literature. The aim of this study is to analyze the association between HFI and NAFLD in treated patients. A cross-sectional observational study was conducted. The population comprised 16 genetically diagnosed HFI patients aged from 3 years to 48 and in dietary treatment of fructose, sorbitol and sacarose exclusion at least for two years. Blood samples were obtained for analytical studies and anthropometric measurements of each patient were performed. Patients presented a Body Mass Index (BMI) of 17.9 ± 2.9 kg/m2. The HOMA index and Quick index were in normal range for our population. The S-adenosyl-methionine (SAM)/S-adenosyl-l-homocysteine (SAH) ratio was increased in the patients in whom this analysis was performed. By imaging techniques it was observed that 9 of the 16 patients presented fatty liver (7 by hepatic MRI). Of these 9 patients, only 3 presented hepatomegaly. 7 of 9 patients affected by the c.448G > C mutation had fatty infiltration, of which three of them presented in addition hepatomegaly. There is a high prevalence of fatty liver in HFI patients and it is not related to obesity and insulin resistance. The diagnosis of fatty liver in HFI patients and, above all, the identification of new therapeutic approaches, can positively impact the quality of life of these patients.

26 March 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
ALAlejandro López-Escobar
Alejandro López-Escobar
RMRodrigo Madurga
Rodrigo Madurga
JCJosé María Castellano
José María Castellano
SVSARA VELAZQUEZ
SARA VELAZQUEZ
RCRafael Suarez Del Villar Carrero
Rafael Suarez Del Villar Carrero
SASantiago Ruiz de Aguiar
Santiago Ruiz de Aguiar
Infection by SARS-CoV2 has devastating consequences on health care systems. It is a global health priority to identify patients at risk of fatal outcomes. 1955 patients admitted to HM-Hospitales from 1 March to 10 June 2020 due to COVID-19, were were divided into two groups, 1310 belonged to the training cohort and 645 to validation cohort. Four different models were generated to predict in-hospital mortality. Following variables were included: age, sex, oxygen saturation, level of C-reactive-protein, neutrophil-to-platelet-ratio (NPR), neutrophil-to-lymphocyte-ratio (NLR) and the rate of changes of both hemogram ratios (VNLR and VNPR) during the first week after admission. The accuracy of the models in predicting in-hospital mortality were evaluated using the area under the receiver-operator-characteristic curve (AUC). AUC for models including NLR and NPR performed similarly in both cohorts: NLR 0.873 (95% CI: 0.849–0.898), NPR 0.875 (95% CI: 0.851–0.899) in training cohort and NLR 0.856 (95% CI: 0.818–0.895), NPR 0.863 (95% CI: 0.826–0.901) in validation cohort. AUC was 0.885 (95% CI: 0.885–0.919) for VNLR and 0.891 (95% CI: 0.861–0.922) for VNPR in the validation cohort. According to our results, models are useful in predicting in-hospital mortality risk due to COVID-19. The RIM Score proposed is a simple, widely available tool that can help identify patients at risk of fatal outcomes.

4 July 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
DMDiego Martínez
Diego Martínez
RSRamón Costa Segovia
Ramón Costa Segovia
RCRafael Suarez Del Villar Carrero
Rafael Suarez Del Villar Carrero
CRCarlos Risco-Risco
Carlos Risco-Risco
PFPaula Villares Fernández
Paula Villares Fernández
Diego Martínez-Urbistondo, M.D, Ph. D, Ramón Costa Segovia, M.D, Rafael Suárez del Villar Carrero, M.D, Carlos Risco Risco, M.D., Ph. D, Paula Villares Fernánde

23 February 2023 in Eurosurveillance
Verified
Journal Article
Open access
CRCarlos Risco Risco
Carlos Risco Risco
ZHZaida Herrador
Zaida Herrador
NLNoemí Lopez-Perea
Noemí Lopez-Perea
DMDiego Martínez-Urbistondo
Diego Martínez-Urbistondo
RCRafael Suarez Del Villar Carrero
Rafael Suarez Del Villar Carrero
JMJosefa Masa-Calles
Josefa Masa-Calles
Background: Herpes zoster (HZ) affects 1 in 3 persons in their lifetime, and the risk of HZ increases with increasing age and the presence of immunocompromising conditions. In Spain, vaccination guidelines were recently updated to include the recommendation of the new recombinant zoster vaccine (RZV) for certain risk groups. Aim: To describe the epidemiology of HZ-related hospitalisations in Spain in order to prioritise vaccination recommendations and define a baseline to monitor the effectiveness of vaccination policies. Methods: Retrospective study using the National Health System’s Hospital Discharge Records Database, including all HZ-related hospitalisations from 1998 to 2018. Results: The 65,401 HZ-related hospitalisations, corresponded to an annual mean hospitalisation rate of 6.75 per 100,000 population. There was an increasing trend of HZ hospitalisations over the study period. This rate was higher in males and older age groups, particularly over 65 years. Comorbidities with higher risk of readmission were leukaemia/lymphoma (RR 2.4; 95% CI: 2.3–2.6) and solid malignant neoplasm (RR 2.2; 95% CI: 2.1–2.4). Comorbidities associated with higher risk of mortality were leukaemia/lymphoma (RR 2.9; 95% CI: 2.7–3.2), solid malignant neoplasm (RR 2.9; 95% CI: 2.7–3.1) and HIV infection (RR 2.2; 95% CI: 1.8–2.7). Conclusion: Of all patients hospitalised with HZ, those with greater risk of mortality or readmission belonged to the groups prioritised by the current vaccination recommendations of the Spanish Ministry of Health. Our study provided relevant information on clinical aspects of HZ and established the base for future assessments of vaccination policies.

13 November 2020 in Antioxidants
Verified
Journal Article
Open access
PDF file
DMDiego Martinez-Urbistondo
Diego Martinez-Urbistondo
RCRafael Suarez Del Villar Carrero
Rafael Suarez Del Villar Carrero
JAJosepmaria Argemi
Josepmaria Argemi
LRLidia Ruiz
Lidia Ruiz
OROmar Ramos-Lopez
Omar Ramos-Lopez
JMJ. Alfredo Martinez
J. Alfredo Martinez
The assessment of liver fibrosis has gained importance since the progression of non-alcoholic fatty liver disease (NAFLD). Indeed, the description of the association between undetected liver fibrosis and lifestyle in terms of antioxidant habits, comorbidity and quality of life (QoL) domains may help in the characterization of subjects with NAFLD. A cross-sectional evaluation of (n = 116) consecutive patients from an Internal Medicine ambulatory evaluation was performed. Demographic data, lifestyle, co-morbidity, QoL (according to the SF-36 index) and analytical values to calculate the oxidative related Fibrosis-4 (FIB-4) index were recorded. The association between FIB-4 and co-morbidity, antioxidant habits in QoL was assessed in univariate analysis (p < 0.05) and confirmed in multivariable analysis for 4 of the 8 SF-36 categories: Physical QoL, Physical role, Social QoL and General QoL, as well as in the Physical summary of SF-36 (p < 0.05). Finally, interactions were assessed between co-morbidity, FIB-4 and antioxidant habits showed in the prediction of mean SF-36 (p < 0.01). Liver fibrosis assessed by the oxidative surrogate index FIB-4 is associated with the interaction between antioxidant lifestyle, co-morbidity and physical, social and general aspects of QoL in apparent liver disease-free individuals, generating a proof of concept for health empowerment and personalized medicine.

18 April 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JGJesus García-Donas
Jesus García-Donas
DMDiego Martínez-Urbistondo
Diego Martínez-Urbistondo
KKKyra Velázquez Kennedy
Kyra Velázquez Kennedy
PVPaula Villares
Paula Villares
ABArántzazu Barquin
Arántzazu Barquin
RMRodrigo Madurga
Rodrigo Madurga
Background: Managing the inflammatory response to SARS-Cov-2 could prevent respiratory insufficiency. Cytokine profiles could identify cases at risk of severe disease.Methods: We designed a randomized phase II clinical trial to determine whether the combination of ruxolitinib (5 mg twice a day for 7 days followed by 10 mg BID for 7 days) plus simvastatin (40 mg once a day for 14 days), could reduce the incidence of respiratory insufficiency in COVID-19. 48 cytokines were correlated with clinical outcome.Participants: Patients admitted due to COVID-19 infection with mild disease.Results: Up to 92 were included. Mean age was 64 ± 17, and 28 (30%) were female. 11 (22%) patients in the control arm and 6 (12%) in the experimental arm reached an OSCI grade of 5 or higher (p = 0.29). Unsupervised analysis of cytokines detected two clusters (CL-1 and CL-2). CL-1 presented a higher risk of clinical deterioration vs CL-2 (13 [33%] vs 2 [6%] cases, p = 0.009) and death (5 [11%] vs 0 cases, p = 0.059). Supervised Machine Learning (ML) analysis led to a model that predicted patient deterioration 48h before occurrence with a 85% accuracy.Conclusions: Ruxolitinib plus simvastatin did not impact the outcome of COVID-19. Cytokine profiling identified patients at risk of severe COVID-19 and predicted clinical deterioration.Trial registration: https://clinicaltrials.gov/, identifier NCT04348695.